SGLT2 Inhibitor Cancer Risk Meta-Analysis: 28 RCTs and 98,297 Participants

A systematic review and meta-analysis of 28 randomized controlled trials published up to April 16, 2024, involving 98,297 participants. The study, authored by Jing Teng and registered in PROSPERO, assesses the long-term safety of SGLT2 inhibitors regarding cancer risk in patients with Type 2 diabetes, heart failure, and chronic kidney disease.

Use Cases

• Assessing overall cancer risk associated with SGLT2 inhibitors based on pooled risk ratios from the meta-analysis.
• Evaluating drug safety in specific patient populations (e.g., heart failure, chronic kidney disease) based on subgroup analyses mentioned.
• Comparing cancer risk across different types of SGLT2 inhibitors as referenced in the results.
• Investigating associations with specific cancer types (e.g., breast cancer, bladder cancer) as secondary outcomes.

Strengths

• Analysis is based on 28 randomized controlled trials, a study design that suggests a structured evidence base.
• Includes data from 98,297 participants, providing a substantial sample size for the meta-analysis.
• Registered in PROSPERO (CRD42024560310), indicating a predefined protocol.
• Uses pooled risk ratios with 95% confidence intervals for outcome reporting.

Limitations

• The dataset is a 266.3 KB DOCX document; the underlying tabular data (e.g., forest plots, study-level data) is not directly accessible as a structured table.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for any underlying data tables is unknown, which may limit suitability assessment.

Provenance

Source

figshare, author Jing Teng.

Collection Method

Systematic review and meta-analysis of studies from PubMed, CENTRAL, Web of Science, and ClinicalTrials.gov.

Time Range

Studies published up to April 16, 2024.

Freshness

Last updated 2026-05-08 05:57:08; freshness should be verified.